CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 2 (2021) Vis Cancer Med, 2 (2021) 1 References
Open Access
Issue
Vis Cancer Med
Volume 2, 2021
Article Number 1
Number of page(s) 9
DOI https://doi.org/10.1051/vcm/2020002
Published online 03 March 2021
  1. Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 2018;18(6):359–76. [PubMed] [Google Scholar]
  2. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52. [Google Scholar]
  3. Ghirelli C, Hagemann T. Targeting immunosuppression for cancer therapy. J Clin Invest. 2013;123(6):2355–7. [PubMed] [Google Scholar]
  4. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. [CrossRef] [PubMed] [Google Scholar]
  5. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010;15(4):411–21. [PubMed] [Google Scholar]
  6. Katz OB, Shaked Y. Host effects contributing to cancer therapy resistance. Drug Resist Updat. 2015;19:33–42. [PubMed] [Google Scholar]
  7. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;27(5 Suppl 9):13–9. [Google Scholar]
  8. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205–18. [CrossRef] [PubMed] [Google Scholar]
  9. Nguyen AN, Stebbins EG, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res. 2006;312(10):1909–23. [PubMed] [Google Scholar]
  10. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell. 2019;176(3):677. [PubMed] [Google Scholar]
  11. Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46–62. [PubMed] [Google Scholar]
  12. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. [PubMed] [Google Scholar]
  13. Wherry EJ, Blattman JN, Murali-Krishna K, et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911–27. [Google Scholar]
  14. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. [Google Scholar]
  15. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–86. [Google Scholar]
  16. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. [Google Scholar]
  17. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71. [PubMed] [Google Scholar]
  18. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62. [CrossRef] [PubMed] [Google Scholar]
  19. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. [CrossRef] [PubMed] [Google Scholar]
  20. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. [Google Scholar]
  21. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1. [Google Scholar]
  22. Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. [Google Scholar]
  23. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. [CrossRef] [PubMed] [Google Scholar]
  24. Spranger S, Luke JJ, Bao R, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA. 2016;113(48):E7759–E68. [Google Scholar]
  25. Danilova L, Wang H, Sunshine J, et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA. 2016;113(48):E7769–E77. [Google Scholar]
  26. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30. [CrossRef] [PubMed] [Google Scholar]
  27. Zhang Y, Chen L. Classification of advanced human cancers based on Tumor Immunity in the MicroEnvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2(11):1403–4. [PubMed] [Google Scholar]
  28. Murciano-Goroff YR, Warner AB, Wolchok JD, The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19. [PubMed] [Google Scholar]
  29. Harrington KJ, Puzanov I, Hecht JR, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15(12):1389–403. [PubMed] [Google Scholar]
  30. Pan RY, Chung WH, Chu MT, et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874. [PubMed] [Google Scholar]
  31. Lin JR, Izar B, Wang S, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018;7. [Google Scholar]
  32. Stack EC, Wang C, Roman KA, et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70(1):46–58. [PubMed] [Google Scholar]
  33. Dixon AR, Bathany C, Tsuei M, et al. Recent developments in multiplexing techniques for immunohistochemistry. Expert Rev Mol Diagn. 2015;15(9):1171–86. [PubMed] [Google Scholar]
  34. Walch A, Rauser S, Deininger SO, et al. MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem Cell Biol. 2008;130(3):421–34. [PubMed] [Google Scholar]
  35. Giesen C, Wang HA, Schapiro D, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417–22. [PubMed] [Google Scholar]
  36. Aichler M, Walch A. MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95(4):422–31. [Google Scholar]
  37. Ahmed M, Broeckx G, Baggerman G, et al. Next-generation protein analysis in the pathology department. J Clin Pathol. 2020;73(1):1–6. [PubMed] [Google Scholar]
  38. Angelo M, Bendall SC, Finck R, et al. Multiplexed ion beam imaging of human breast tumors. Nat Med. 2014;20(4):436–42. [PubMed] [Google Scholar]
  39. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22–9. [PubMed] [Google Scholar]
  40. Stahl PL, Salmen F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78–82. [Google Scholar]
  41. Vickovic S, Eraslan G, Salmen F, et al. High-definition spatial transcriptomics for in situ tissue profiling. Nat Methods. 2019;16(10):987–90. [PubMed] [Google Scholar]
  42. Merritt CR, Ong GT, Church SE, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586–99. [PubMed] [Google Scholar]
  43. Lee J, Geiss GK, Demirkan G, et al. Implementation of a multiplex and quantitative proteomics platform for assessing protein lysates using DNA-barcoded antibodies. Mol Cell Proteomics. 2018;17(6):1245–58. [Google Scholar]
  44. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–25. [PubMed] [Google Scholar]
  45. Beechem JM. High-plex spatially resolved rna and protein detection using digital spatial profiling: A technology designed for immuno-oncology biomarker discovery and translational research. Methods Mol Biol. 2020;2055:563–83. [PubMed] [Google Scholar]
  46. Decalf J, Albert ML, Ziai J, New tools for pathology: a user’s review of a highly multiplexed method for in situ analysis of protein and RNA expression in tissue. J Pathol. 2019;247(5):650–61. [Google Scholar]
  47. Toki MI, Merritt CR, Wong PF, et al. High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling. Clin Cancer Res. 2019;25(18):5503–12. [PubMed] [Google Scholar]
  48. Zugazagoitia J, Gupta S, Liu Y, et al. Biomarkers associated with beneficial PD-1 checkpoint blockade in Non-Small-Cell Lung Cancer (NSCLC) identified using high-plex digital spatial profiling. Clin Cancer Res. 2020. [Google Scholar]
  49. Sautes-Fridman C, Petitprez F, Calderaro J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–25. [Google Scholar]
  50. Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. [CrossRef] [PubMed] [Google Scholar]
  51. Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54. [CrossRef] [PubMed] [Google Scholar]
  52. Rozeman EA, Prevoo W, Meier MAJ, et al. Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Res. 2020;30(3):252–60. [PubMed] [Google Scholar]
  53. Farren MR, Sayegh L, Ware MB, et al. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI. Insight. 2020;5(1). [Google Scholar]
  54. Koelzer VH, Sirinukunwattana K, Rittscher J, et al. Precision immunoprofiling by image analysis and artificial intelligence. Virchows Arch. 2019;474(4):511–22. [PubMed] [Google Scholar]
  55. Van TM, Blank CU. A user’s perspective on GeoMxTM digital spatial profiling. Immuno-Oncol Technol. 2019;1:11–8. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.